IDH inhibitor resistance has been reported in adults with AML through trans or cis dimer-interface mutations (144), receptor tyrosine kinase (RTK) pathway mutations (145) or second site mutations (146, 147). The gene discussed is IDH1; the disease is acute myeloid leukemia.